Table 3.
Adverse events during the follow-up period
| TwHF group (n = 34) | Valsartan group (n = 31) | |
|---|---|---|
| Any adverse event (n,%) |
13 (38.3) |
12 (38.7) |
| Vomiting (n,%) |
1 (2.94) |
0 (0.00) |
| Liver dysfunction (n,%) |
3 (8.82) |
0 (0.00) |
| Decrease in WBC count (n,%) |
1 (2.94) |
0 (0.00) |
| Photosensitive dermatitis (n,%) |
0 (0.00) |
1 (3.22) |
| Hyperkalemia (n,%) |
8 (23.53) |
10 (32.2) |
| K+ > 6.0 (n,%) |
3 (8.82) |
2 (6.45) |
| Doubling of serum creatinine (n,%) | 0 (0.00) | 1 (3.22) |